concept

NAD

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NAD: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1097Connections

12Hypotheses

2Analyses

50Outgoing

50Incoming

7Experiments

2Debates

Summary

NAD is a concept in neurodegeneration research. Key relationships include: activates, regulates, associated with. Associated with AD, ADH, ALI. Connected to 546 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	NAD
Key Genes/Proteins	ABCA7, ACC, Actin, Adiponectin, ADORA2B, AGING
Related Diseases	AD, Addiction, ADH, aging, Aging
Linked Hypotheses	16 hypotheses

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    NAD["NAD"]
    NAD -->|"regulates"| neuronal_bioenergetics["neuronal bioenergetics"]
    NAD -->|"regulates"| oxidative_stress["oxidative stress"]
    NAD -->|"regulates"| epigenetic_changes["epigenetic changes"]
    NAD -->|"regulates"| Tumor["Tumor"]
    NAD -->|"regulates"| Neurodegeneration["Neurodegeneration"]
    NAD -->|"regulates"| Cancer["Cancer"]
    NAD -->|"regulates"| Autoimmune["Autoimmune"]
    NAD -->|"activates"| Aging["Aging"]
    NAD -->|"regulates"| Cardiovascular["Cardiovascular"]
    NAD -->|"causes"| Inflammation["Inflammation"]
    cd38["cd38"] -->|"regulates"| NAD
    P7C3_A20["P7C3-A20"] -->|"activates"| NAD
    ATP["ATP"] -->|"causes"| NAD
    CD38["CD38"] -->|"regulates"| NAD
    CIRCADIAN_RHYTHM["CIRCADIAN RHYTHM"] -->|"regulates"| NAD
    DNA["DNA"] -->|"contributes to"| NAD
    SIRT6["SIRT6"] -->|"inhibits"| NAD
    EGR2["EGR2"] -->|"inhibits"| NAD
    PARP1["PARP1"] -->|"inhibits"| NAD

Outgoing (825)

Target	Relation	Type	Str
Inflammation	activates	disease	1.00
Aging	regulates	disease	1.00
SIRT1	regulates	gene	1.00
Als	regulates	disease	1.00
AGING	activates	gene	1.00
Aging	activates	disease	1.00
Als	activates	disease	1.00
MITOCHONDRIA	activates	gene	1.00
SIRT1	associated_with	gene	1.00
AGING	regulates	gene	1.00
SIRT1	activates	gene	1.00
Cancer	activates	disease	0.95
Energy Metabolism	involved_in	process	0.95
Neurodegeneration	activates	disease	0.95
DNA Repair	involved_in	process	0.95
Inflammation	regulates	disease	0.95
Redox Metabolism	involved_in	process	0.95
Obesity	activates	disease	0.95
Cancer	regulates	disease	0.95
aging	associated_with	disease	0.90
Aging	associated_with	phenotype	0.90
NAMPT	associated_with	gene	0.90
Immune Response	involved_in	process	0.90
SIRT3	activates	protein	0.90
aging	activates	disease	0.90
Mtor	activates	pathway	0.90
OXIDATIVE STRESS	activates	gene	0.90
Oxidative Stress	activates	pathway	0.90
NEURODEGENERATION	activates	gene	0.90
MITOCHONDRIAL DYSFUNCTION	activates	gene	0.90
Oxidative Phosphorylation	activates	pathway	0.90
Glycolysis	activates	pathway	0.90
AMPK	activates	gene	0.90
APOPTOSIS	therapeutic_target	gene	0.90
CANCER	activates	gene	0.90
Apoptosis	therapeutic_target	pathway	0.90
INFLAMMATION	activates	gene	0.90
NEURODEGENERATIVE DISEASES	activates	gene	0.90
CANCER	regulates	gene	0.90
Tumor	regulates	disease	0.85
Parkinson	activates	disease	0.85
Cancer	associated_with	disease	0.85
Alzheimer	activates	disease	0.85
Senescence	therapeutic_target	disease	0.85
DAM microglia	expressed_in	cell_type	0.85
Aging	associated_with	disease	0.85
NAD+ metabolism	participates_in	pathway	0.85
Inflammation	therapeutic_target	disease	0.85
Diabetes	activates	disease	0.85
senescence	participates_in	pathway	0.80

Incoming (272)

Source	Relation	Type	Str
Dietary Restriction	modulates	process	0.85
cd38	regulates	gene	0.85
nicotinamide	targets	drug	0.85
CD38	catalyzes	protein	0.85
CD38	regulates	gene	0.85
CD38	associated_with	gene	0.70
ATP	associated_with	gene	0.70
AGING	associated_with	gene	0.70
P7C3-A20	activates	drug	0.70
DNA	disrupts	gene	0.70
ALZHEIMER'S DISEASE	associated_with	disease	0.65
ATP	regulates	gene	0.65
ENDOTHELIAL	regulates	cell_type	0.65
APP	inhibits	gene	0.65
BMAL1	activates	gene	0.65
CLOCK	activates	gene	0.65
CANCER	interacts_with	disease	0.65
MACROPHAGE	activates	cell_type	0.65
MONOCYTE	activates	cell_type	0.65
AMPK	activates	gene	0.65
MTOR	regulates	gene	0.65
PARKINSON'S DISEASE	activates	gene	0.60
OVERVIEW	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
OXIDATIVE STRESS	activates	gene	0.60
INFLAMMATION	activates	gene	0.60
AND	activates	gene	0.60
AMPK	therapeutic_target	gene	0.60
APOPTOSIS	therapeutic_target	gene	0.60
AND	associated_with	gene	0.60
RPA2	regulates	gene	0.60
GLUCONEOGENIC GENES	regulates	gene	0.60
ALZHEIMER DISEASE	associated_with	gene	0.60
AND	therapeutic_target	gene	0.60
MICROGLIA	activates	gene	0.60
AGING	causes	gene	0.60
NAMPT	causes	gene	0.60
AND	causes	gene	0.60
MYC	activates	gene	0.60
DRP1	regulates	gene	0.60
HMOX1	activates	gene	0.60
TFEB	regulates	gene	0.60
TFAM	activates	gene	0.60
CALCINEURIN	regulates	gene	0.60
PARKINSON	expressed_in	gene	0.60
MITOCHONDRIA	associated_with	gene	0.60
ALZHEIMER	expressed_in	gene	0.60
AND	expressed_in	gene	0.60
BRAIN INJURY	associated_with	gene	0.60
AXON	activates	gene	0.60

Targeting Hypotheses (12)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
PARP1-NAD+-AIF bioenergetic collapse drives a self-amplifyin	0.760	neurodegeneration	What mechanisms drive the self-amplifyin
Senescence-Activated NAD+ Depletion Rescue	0.755	neurodegeneration	Senolytic therapy for age-related neurod
Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove	0.745	neurodegeneration	Epigenetic reprogramming in aging neuron
Metabolic Inflexibility Precedes Transcriptional Reprogrammi	0.735	neurodegeneration	What is the optimal therapeutic window f
NAD+ Decline and SIRT1 Deficiency Drive Epigenetic Reprogram	0.700	neurodegeneration	What molecular mechanisms drive microgli

SARM1-Mediated NAD+ Depletion as Terminal Executor of MCT1-D	0.698	neurodegeneration	What is the molecular mechanism by which
SIRT6-NAD+ Axis Enhancement Therapy	0.667	neurodegeneration	Epigenetic clocks and biological aging i
Mitochondrial NAD+ Salvage Enhancement	0.639	neurodegeneration	Gene expression changes in aging mouse b
NAMPT-Centered NAD+ Restoration to Reverse Basal Forebrain C	0.616	neurodegeneration	Do β-amyloid plaques and neurofibrillary
NAD+/SARM1 Axis Provides Metabolic Feedback Coupling Mitopha	0.578	neurodegeneration	How do different organelle-specific auto
CD38 Inhibition for NAD+ Restoration and Microglial Senescen	0.575	neurodegeneration	Microglial subtypes in neurodegeneration
NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) P	0.520	metabolomics	Metabolomic signatures of neurodegenerat

Mentioning Analyses (2)

Scientific analyses that reference this entity

Do β-amyloid plaques and neurofibrillary tangles cause or result from cholinergi

neurodegeneration | 2026-04-16 | 2 hypotheses Top: 0.616

Metabolomic signatures of neurodegeneration and energy metabolism dysfunction

neurodegeneration | 2026-04-04 | 0 hypotheses

Experiments (7)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Sirtuin Pathway Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,500,000
Microglial Aging and Immune Memory in Neurodegeneration — Training the	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$2,960,000
Normal Aging to Alzheimer's Disease Transition Trigger — Identifying t	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$2,280,000
Peroxisomal Dysfunction Validation in Parkinson's Disease	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,280,000
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Sirtuin Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and De [PMID:38580317]	Velma GR, Krider IS, Alves ETM, Courey J	J Med Chem	2024	1
SIRT6-regulated macrophage efferocytosis epigenetically controls inflammation re [PMID:36593966]	Li B, Xin Z, Gao S, Li Y, Guo S, Fu Y, X	Theranostics	2023	1
Assessing the Status of Mandatory Tuberculosis Case Notification among Private P [PMID:35068738]	Duggal K, Elsy M, Majella MG, Akkilagunt	Indian J Community Med	2021	1
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic [PMID:33888596]	Yoshino M, Yoshino J, Kayser BD, Patti G	Science	2021	1
NAD(+) metabolism, stemness, the immune response, and cancer. [PMID:33384409]	Navas LE, Carnero A	Signal Transduct Target Ther	2021	1
Protocol for the Bottom-Up Proteomic Analysis of Mouse Spleen. [PMID:33377090]	Dowling P, Gargan S, Zweyer M, Henry M,	STAR Protoc	2020	1
Dynamic Acetylation of Phosphoenolpyruvate Carboxykinase Toggles Enzyme Activity [PMID:30193097]	Latorre-Muro P, Baeza J, Armstrong EA, H	Mol Cell	2018	1
NAD metabolism fuels human and mouse intestinal inflammation. [PMID:28877980]	Gerner RR, Klepsch V, Macheiner S, Arnha	Gut	2018	1
The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcin [PMID:28329682]	Nargund AM, Pham CG, Dong Y, Wang PI, Os	Cell Rep	2017	1
Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype [PMID:26686024]	Wiley CD, Velarde MC, Lecot P, Liu S, Sa	Cell Metab	2016	1
NAD+ and sirtuins in aging and disease. [PMID:24786309]	Imai S, Guarente L	Trends Cell Biol	2014	1
Mitochondrial NAD(+)-mediated mitophagy alleviates type I interferon response to [PMID:41231107]	Lan T, Shang D, Lin L, Wang H, Zou J et	Autophagy	2026	0
SIRT6 inhibits intermittent hypoxia-induced lung injury by stabilizing NRF2. [PMID:41478020]	Qin R, Liu Z, Li R, Li Y, Yang Y et al.	Tissue Cell	2026	0
cGAS-STING signaling in Alzheimer's disease: Microglial mechanisms and therapeut [PMID:41481960]	Fazal F, Dar NJ, Ahamad S, Khan S, Bano	Mol Aspects Med	2026	0
Opportunities and challenges of targeting cGAS-STING in cancer. [PMID:41486397]	Lu C, Wang W, Fu YX	Nat Rev Cancer	2026	0
CircZBTB44-Encoded Peptide ZBTB44-342aa Alleviates Aortic Valve Calcification Vi [PMID:41487094]	Hu D, Lin Y, Huang H, Xian G, Chen Y et	Circ Res	2026	0
Inhibiting macrophage-derived lactate transport restores cGAS-STING signalling a [PMID:41495200]	Li D, Cui G, Yang K, Lu C, Jiang Y et al	Nat Cell Biol	2026	0
cGAS-STING activation in Parkinson's Disease: From mechanisms to Disease-Modifyi [PMID:41500413]	Solomon J, Mandal S, Aran KR	Gene	2026	0
Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated im [PMID:41512867]	Li L, Ye Q, Ma J, Wang Z, Liu T et al.	Cancer Cell	2026	0
Inflammation-targeted single-atom nanozymes drive microglial depolarization and [PMID:41624511]	Liu B, Xiang C, Zhang X, Guo W, Wu H et	Mater Today Bio	2026	0

Debates (2)

Multi-agent debates referencing this entity

How do metabolomic alterations in glucose metabolism, mitochondrial function, an

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

The abstract explicitly questions whether AD's hallmark pathologies induce choli

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

NAD

Understanding Entity Pages

Summary

Wiki Pages (21)

ChromaDex

Epigenetic-Metabolic Coupling: SIRT1 Activator + NAD+ Precursor

NAD+ Precursors for Neurodegeneration

Infantile Neuroaxonal Dystrophy (INAD)

Section 103: Sirtuin Pathway and NAD+-Dependent Deacetylases in CBS/PSP

NAD+ Metabolism in Neurodegeneration

NDUFS8 — NADH:Ubiquinone Oxidoreductase Core Subunit S8

NADK Gene

SARM1 NADase Inhibition for Axonal Preservation

NDUFAF2 — NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2

Mitochondrial NAD Redox Swing Protocol with Temporal Dosing Windows

NAD Signaling in Neurodegeneration

Mitochondrial NAD Redox Swing Protocol with Temporal Dosing Windows

NAD+ Metabolism Pathway in Neurodegeneration

NQO1 Protein (NAD(P)H Quinone Dehydrogenase 1)

NAD+ Precursors (NMN/NR) for Parkinson's Disease

Infantile Neuroaxonal Dystrophy (INAD) Pathway

NDUFAF4 — NADH Dehydrogenase Complex Assembly Factor 4

NDUFS5 — NADH:Ubiquinone Oxidoreductase Core Subunit S5

NAD+ Bioenergetics Investment Synthesis

SARM1 NADase Inhibition Therapy